Core Viewpoint - On October 22, Tiger Med experienced a decline of 0.89% with a trading volume of 327 million yuan, indicating a negative net financing position for the day [1] Financing Summary - On October 22, Tiger Med had a financing buy-in amount of 30.85 million yuan and a financing repayment of 39.86 million yuan, resulting in a net financing outflow of 9.01 million yuan [1] - As of October 22, the total financing and securities lending balance for Tiger Med was 783 million yuan, with the financing balance accounting for 1.99% of the circulating market value, which is above the 60th percentile level over the past year [1] Securities Lending Summary - On October 22, Tiger Med repaid 12,500 shares in securities lending and sold 8,100 shares, amounting to 431,100 yuan based on the closing price [1] - The securities lending balance stood at 323,640 yuan with a remaining quantity of 60,800 shares, exceeding the 70th percentile level over the past year [1] Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province, and specializes in providing professional clinical research services for pharmaceutical and health-related products [2] - The company's main business revenue composition includes 52.60% from clinical trial-related services and laboratory services, and 45.21% from clinical trial technical services [2] Financial Performance - For the first half of 2025, Tiger Med reported a revenue of 3.25 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 383 million yuan, down 22.22% year-on-year [2] Dividend Information - Since its A-share listing, Tiger Med has distributed a total of 2.458 billion yuan in dividends, with 1.154 billion yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, Tiger Med had 51,500 shareholders, a decrease of 4.14% from the previous period [2] - The top circulating shareholders include China Europe Medical Health Mixed Fund, Hong Kong Central Clearing Limited, and Huabao CSI Medical ETF, with varying changes in their holdings [3]

Group 1 - The medical sector experienced volatility, with the largest medical ETF in A-shares (512170) dropping over 2% in the afternoon, with real-time transactions exceeding 490 million yuan [1] - The ETF's latest scale is 25.73 billion yuan, ranking first among similar ETFs [1] - Notable declines were observed in constituent stocks, with Sanbo Brain Science falling over 6%, and other companies like Yingke Medical and Nanwei Medical dropping more than 4% [1] Group 2 - Ping An Securities indicated that the bidding environment for medical devices will remain favorable in 2025, with strong demand for ultrasound, CT, and MRI equipment driven by policy incentives [3] - The pharmaceutical and biotechnology sectors are currently affected by policy disruptions, but the long-term industry trend remains unchanged, with Chinese innovative drug companies gaining global competitiveness [3] - The medical ETF (512170) passively tracks the CSI Medical Index, with its top ten weighted stocks including WuXi AppTec, Mindray Medical, and others [3]

Group 1 - The core point of the article is that E Fund Management Co., Ltd. has increased its stake in Tiger Med (03347.HK) by purchasing 573,100 shares at an average price of HKD 42.0922 per share, totaling approximately HKD 24.123 million [1] - After the purchase, E Fund's total shareholding in Tiger Med reached 10,360,100 shares, raising its ownership percentage from 7.95% to 8.41% [1][2]

智通财经APP获悉，香港联交所最新数据显示，10月13日，易方达基金管理有限公司增持泰格医药 (03347)57.31万股，每股作价42.0922港元，总金额约为2412.3万港元。增持后最新持股数目为1036.01万 股，持股比例为8.41%。 ...

香港联交所最新数据显示，10月13日，易方达基金管理有限公司增持泰格医药（300347）(03347)57.31 万股，每股作价42.0922港元，总金额约为2412.3万港元。增持后最新持股数目为1036.01万股，持股比 例为8.41%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 董事長 葉小平 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 承董事會命 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 董事會會議召開日期 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於2025年10月28日（星 期 二）舉 行，藉 以（其 中 包 括） 審議及批准本公司及其附屬公司截至2025年9月30日止九個月的第三季 度 報 告 及╱或 其 他 議 題（如 適 用）。 香 港，2025年10月16日 於 本 公 告 日 期，執 行 董 事 為 葉 小 平 博 士、曹 曉 春 女 ...

格隆汇10月16日丨泰格医药(03347.HK)宣布，董事会会议将于2025年10月28日（星期二）举行，藉以 （其中包括）审议及批准本公司及其附属公司截至2025年9月30日止九个月的第三季度报告及╱或其他 议题（如适用）。 ...

（於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於2025年10月28日（星 期 二）舉 行，藉 以（其 中 包 括） 審議及批准本公司及其附屬公司截至2025年9月30日止九個月的第三季 度 報 告 及╱或 其 他 議 題（如 適 用）。 承董事會命 杭州泰格醫藥科技股份有限公司 董事長 （股 份 代 號：3347） 董事會會議召開日期 葉小平 香 港，2025年10月16日 於 本 公 告 日 期，執 行 董 事 為 葉 小 平 博 士、曹 曉 春 女 ...

Core Insights - On October 15, Tiger Med saw a 2.51% increase in stock price with a trading volume of 466 million yuan, while the net financing buy was negative at 336.68 million yuan [1] - The company reported a revenue of 3.25 billion yuan for the first half of 2025, a year-on-year decrease of 3.21%, and a net profit of 383 million yuan, down 22.22% year-on-year [2] Financing and Margin Trading - On October 15, Tiger Med had a financing buy of 36.32 million yuan and a financing repayment of 39.69 million yuan, resulting in a total financing balance of 7.54 billion yuan [1] - The current financing balance of 7.51 billion yuan accounts for 1.85% of the market capitalization, which is below the 50th percentile level over the past year, indicating a low position [1] Short Selling - On October 15, Tiger Med repaid 4,900 shares in short selling and sold 2,300 shares, with a selling amount of 126,700 yuan based on the closing price [1] - The short selling balance stands at 375.09 million yuan, which is above the 80th percentile level over the past year, indicating a high position [1] Shareholder Information - As of June 30, 2025, Tiger Med had 51,500 shareholders, a decrease of 4.14% from the previous period [2] - The top ten circulating shareholders include notable funds, with changes in their holdings indicating varying levels of investment interest [3]

Summary of Tigermed (3347.HK) Conference Call Company Overview - **Company**: Tigermed (3347.HK) - **Market Cap**: HK$36.9 billion / $4.7 billion - **Enterprise Value**: HK$40.4 billion / $5.2 billion - **Current Price**: HK$42.70 - **12-Month Price Target**: HK$62.10 (45.4% upside) for H shares; Rmb77.10 (41.9% upside) for A shares [1][6][19] Core Industry Insights - **Industry**: Clinical Contract Research Organization (CRO) in China - **Market Recovery**: Expected inflection point in late 2025 into 2026, driven by increased funding and demand for CRO services [2][20] - **Funding Growth**: Upfront payments from licensing deals reached US$4.6 billion YTD 2025, up 84% year-over-year; total funding via IPOs/FOs at US$13.0 billion, up 517% year-over-year [2][29][30] - **CRO Market Growth**: Anticipated 13% CAGR for the domestic market from 2025 to 2027, with a rising outsourcing rate expected to reach 44% in 2025 [2][22] Financial Performance and Projections - **Earnings Growth**: Tigermed expected to deliver a core earnings CAGR of 37% from 2025 to 2028, with mid-teen revenue growth anticipated [3][46] - **Revenue Estimates**: Projected revenues of Rmb6,747.3 million in 2025, Rmb7,732.5 million in 2026, and Rmb8,907.1 million in 2027 [6][17] - **EPS Growth**: EPS expected to grow from Rmb0.47 in 2024 to Rmb1.84 in 2027, reflecting a significant recovery from previous declines [12][17] Strategic Positioning - **Market Leadership**: Tigermed holds a 13% market share in the Chinese CRO sector, having supported 60% of Class I innovative drugs listed in China [39][45] - **Global Expansion**: The company is enhancing its international presence, particularly in the US, Australia, and Europe, to support both domestic and international clients [43] - **Service Capabilities**: Tigermed's comprehensive R&D service capabilities position it well to capture the anticipated recovery in demand from biotech and pharma clients [43] Risks and Challenges - **Market Risks**: Potential geopolitical and regulatory challenges, slower-than-expected demand recovery, and ongoing pressure from impairment [19] - **Pricing Dynamics**: Pricing stabilized after a significant drop in 2023-2024, but true margin comparability will not be evident until late 2026 [35] Additional Insights - **Order Intake**: New order intake showing signs of recovery, with a mid-teen percentage increase reported in early 2025 [21][46] - **Book-to-Bill Ratio**: Expected to recover to 1.5x in 2025 from 1.1x/1.3x in 2023/2024, indicating a positive outlook for future revenue growth [50][52] - **Consolidation Potential**: The CRO market in China is fragmented, suggesting opportunities for consolidation as firms pursue licensing and business development deals [39][40] This summary encapsulates the key points from the conference call regarding Tigermed's current position, industry dynamics, financial outlook, and strategic initiatives.